The Europe biosimilars market size is expected to grow from US$ 10,344.86 million in 2022 to US$ 115,125.91 million by 2030; it is estimated to grow at a CAGR of 35.1% from 2022 to 2030.
Analyst’s ViewPoint
One of the most impacting factors responsible for influential growth of Europe biosimilars market is the increasing prevalence of chronic diseases. Further, patent expiry of blockbuster biologics acts as a future trend for the market to grow during 2022–2030. According to the segmentation profiled in the report, based on disease indication, the cancer segment accounts the highest share; based on route of administration, the intravenous segment dominates the market accounting maximum share. In terms of drug class, the granulocyte colony-stimulating factor segment will account considerable share of the biosimilars market and will dominate the market during the forecast period. By distribution channel, the rheumatologists segment is likely to account for a maximum share during 2022–2030.
Biosimilars are safe and effective treatment options intended for many illnesses, such as chronic skin and bowel diseases (psoriasis, irritable bowel syndrome, Crohn's disease and colitis), arthritis, kidney conditions, and cancer. Also, biosimilars increase access to lifesaving medications at potentially lower costs.
Market Insights
Increasing Prevalence of Chronic Diseases
Increasing aging population, changing social behavior, and rising adoption of a sedentary lifestyle by people, along with accelerating urbanization, boost the prevalence of obesity and various chronic diseases, such as diabetes. Also, twin studies have long established that genes can cause chronic conditions such as cardiovascular disease (CVDs), diabetes, obesity, Alzheimer's disease (AD), and depression.
As per the World Health Organization (WHO) report, chronic diseases are a leading cause of mortality in Europe, with complex conditions such as diabetes accounting for a large burden. The European Chronic Disease Alliance 2022 report reveals that chronic diseases such as heart disease, stroke, cancer, chronic respiratory diseases, and diabetes are major causes of mortality in Europe, representing 77% of the total disease burden and 86% of all deaths.
Recognition of biosimilars as efficacious and safe agents by patients, specialists, primary care clinicians, and other healthcare professionals is propelling the demand for biosimilars. In addition, biosimilars help improve the quality of life for millions of patients while saving billions of dollars of the healthcare system per year. They are effective and cost-effective options in treating many diseases, including chronic skin conditions and bowel diseases such as Crohn's disease, psoriasis, irritable bowel syndrome, and colitis; diabetes; autoimmune disease; cancer; kidney conditions; and arthritis.
According to the American Society of Clinical Oncology 2023 report, in the European Union (EU), the first biosimilar was approved in 2006, and since then, the European Medicines Agency (EMA) approved 99 biosimilars for a wide range of therapeutic areas. By 2020, biosimilar adoption in Europe achieved a positive impact on market competition, generating cost savings of US$ 5.7 billion.
As the prevalence of chronic diseases is increasing at a high rate in Europe, the demand for biosimilars in treating life-threatening illnesses has progressed rapidly over the last five years, which is driving the biosimilars market in Europe accounting considerable market share.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Europe Biosimilars Market: Strategic Insights
Market Size Value in US$ 10,344.86 million in 2022 Market Size Value by US$ 115,125.91 million by 2030 Growth rate CAGR of 35.1% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Europe Biosimilars Market: Strategic Insights
| Market Size Value in | US$ 10,344.86 million in 2022 |
| Market Size Value by | US$ 115,125.91 million by 2030 |
| Growth rate | CAGR of 35.1% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Disease Indication Insights
Based on disease indication, the Europe biosimilars market is segmented as cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2022 and will account a significant CAGR in the biosimilars market during the forecast period. Biosimilars have been used in many disease areas, including oncology. They are safe and effective. Also, they lower drug costs and are accessible to more patients worldwide. The treatment of cancer continues to place a significant burden on healthcare systems, with the number of cancer cases continuing to rise due to an aging population.
According to the Centers for Disease Control and Prevention (CDC), each year in the UK, ~24,500 men and 10,000 women are diagnosed with cancer, and ~18,600 men and 9,000 women die from the disease. The incidence of cancer has been rising for several decades. Liver cancer is more common in other parts of the world than in the UK. Moreover, according to an article published in Chinese Clinical Oncology (CCO), hepatocellular cancer (HCC) is a leading cause of cancer death worldwide.
A few biosimilars have been approved to treat certain types of cancer, and some have been approved to help manage side effects. FDA-approved biosimilars can be used to treat breast, stomach, colorectal, and other cancers and can also be used to treat side effects of cancer treatments, such as low white blood cell counts that increase the risk of infections. Owing to the above-mentioned factors, the Europe biosimilars market for the segment is likely to propel during the forecast period.
Route of Administration Insights
Based on route of administration, the Europe biosimilars market is segregated as intravenous, subcutaneous, and others. The intravenous segment accounted the largest market share in 2022 and is expected to grow at the highest CAGR during the forecast period. Biosimilars are taken in the same form (injection or intravenous) and dose as the related biologic medication. Patients receiving chemotherapy or other IV therapies might prefer IV administration of trastuzumab to injection as they already have a central venous port in place. Avoiding an additional injection might be preferred over potential time savings. Owing to the above-mentioned factors, the Europe biosimilars market for the segment is likely to propel during the forecast period.
Drug Class Insights
In terms of drug class, the Europe biosimilars market is segmented as granulocyte colony-stimulating factor, insulin, TNF blockers & monoclonal antibodies, and others. The TNF blockers segment accounted the largest biosimilars market share in 2022. The tumor necrosis factor (TNF) blockers are drugs used to stop inflammation and treat inflammatory conditions such as rheumatoid arthritis (RA), psoriatic arthritis, juvenile idiopathic arthritis, inflammatory bowel disease (Crohn's and ulcerative colitis), ankylosing spondylitis, and psoriasis. TNF is currently targeted by four monoclonal antibodies: infliximab, adalimumab, golimumab, and certolizumab. All these agents are effective in the treatment of rheumatoid arthritis (RA), and clinical studies have established their clinical efficacy and their radiographic effectiveness.
Amgen Inc offers FDA-approved biosimilar products Avsola and Riabni for the treatment of RA. Thus, increase in cases of diseases and rise in product approval are driving the Europe biosimilars market for the segment.
Distribution Channel Insights
By distribution channel, the Europe biosimilars market is segmented as endocrinologists, immunologists, rheumatologists, oncologists, dermatologists, retina compounding, and others. The rheumatologists segment held the largest market share in 2022, and the endocrinologists segment will register highest CAGR during the forecast period. Confidence in biosimilars is growing among rheumatologists. The first biosimilar in rheumatology was commercially available through the launching of "Inflectra," an infliximab biosimilar (Remicade). There are four infliximab biosimilars approved, among which three are available in the market with two biosimilars approved. In a survey conducted, 76% of rheumatologists revealed that they were familiar with biosimilars, which was higher than 53% in 2020. Additionally, in 2020, rheumatologists were more comfortable prescribing biosimilars to patients, with 52% revealing that they were comfortable in 2022 compared to 41% in 2020. Therefore, in the coming years, rheumatologists will experience a new way of biosimilars with approved "Adalimumab" biosimilars and launching of the new innovative biosimilars such as "Amjevita" from Amgen, which is anticipated to launch in January 2023. Factors mentioned above will enhance the Europe biosimilars market growth for the segment accounting considerable market share.
Coagulation analyzers Market, by Disease Indication – 2022 and 2030
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Regional Analysis
The European biosimilars market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The growth in the region is driven by growing cardiovascular diseases, increasing thoracic surgeries, increasing incidence of pneumothorax well-developed healthcare infrastructure, an increase in lung transplantation and active key players in the region. Germany accounts maximum share for the Europe biosimilars market. Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare community. Healthcare professionals can treat more patients with high-quality biologics while reducing spending. For example, in Germany, according to Sandoz, the number of daily therapeutic doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) after introducing biosimilars in 2022.
Germany has achieved acceptance of biosimilars with payers, providers, and patients as an integral part of appropriate medicine use. There is full reimbursement from a price set by the company, including immediate patient access to biosimilars. The structure of hospital tendering by multiple buying groups and separate hospital chains allows for competition among manufacturers to be maintained in Germany. For instance, in November 2018, the German Health Ministry introduced a draft bill on safety in the supply of pharmaceuticals. The Gesetz für Mehr Sicherheit in der Arzneimittelversor-gung (GSAV) bill aims to provide a legal framework for the automatic substitution of biosimilars by pharmacists in Germany.
Due to the huge potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. Additionally, in Germany, a law passed in 2019 foresees the automatic substitution of biosimilars in pharmacies beginning in 2022, provided the Federal Joint Committee (the highest decision-making body of the self-governance of health insurers and providers) has determined the interchangeability of the medicines in question, and the prescribing physician has not explicitly excluded it. Therefore, with the growing government initiatives for adopting biosimilars in Germany, the Europe biosimilars market is expected to grow during the forecast period 2022-2030.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Disease Indication, Route of Administration, Drug Class, Distribution Channel, and Region
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Increasing prevalence of chronic diseases and rising approvals of biosimilars are the driving factors responsible for the overall market growth.
Biosimilars are safe and effective treatment options intended for many illnesses, such as chronic skin and bowel diseases (psoriasis, irritable bowel syndrome, Crohn's disease and colitis), arthritis, kidney conditions, and cancer. Also, biosimilars increase access to lifesaving medications at potentially lower costs.
Amgen Inc, Celltrion Inc, Sanofi SA, Biocon Ltd, Samsung Bioepis Co Ltd, Elli Lilly and Co, Sandoz AG, Teva Pharmaceutical Industries Ltd, Pfizer Inc, and Dr. Reddy's Laboratories Ltd, among others are among the leading companies operating in the global Europe biosimilars market.
Based on disease indication, the cancer segment took the forefront lead in the Europe market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
The intravenous segment dominated the global Europe biosimilars market and accounted for the largest revenue in 2022.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Europe Biosimilars Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Biosimilars Market – Market Landscape
4.1 Overview
4.1.1 Europe PEST Analysis
4.2 Actual Market Price/Net Price
4.2.1 France
4.2.2 Germany
4.2.3 Italy
4.2.4 Spain
4.2.5 UK
5. Europe Biosimilars Market
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Rising Approvals of Biosimilars
5.2 Market Restraints
5.2.1 High Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trends
5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis
6. Europe Biosimilars Market – Regional Analysis
6.1 Europe Biosimilars Market Revenue Forecast and Analysis
7. Europe Biosimilars Market – Revenue and Forecast to 2030 – by Disease Indication
7.1 Overview
7.2 Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Autoimmune Diseases
7.5.1 Overview
7.5.2 Autoimmune Diseases: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.5.3 Psoriasis
7.5.3.1 Overview
7.5.4 Psoriasis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.5.5 Arthritis
7.5.5.1 Overview
7.5.6 Arthritis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.5.7 Others
7.5.7.1 Overview
7.5.7.2 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Other Disease Indication
7.6.1 Overview
7.6.2 Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
8. Europe Biosimilars Market Analysis and Forecasts to 2028 – by Route of Administration
8.1 Overview
8.2 Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
8.3 Intravenous
8.3.1 Overview
8.3.2 Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Subcutaneous
8.4.1 Overview
8.4.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9. Europe Biosimilars Market – Revenue and Forecast to 2030 – by Drug Class
9.1 Overview
9.2 Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
9.3 Granulocyte Colony-Stimulating Factor
9.3.1 Overview
9.3.2 Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Insulin
9.4.1 Overview
9.4.2 Insulin: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9.5 TNF Blockers and Monoclonal Antibodies
9.5.1 Overview
9.5.2 TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10. Europe Biosimilars Market – Revenue and Forecast to 2030 – by Distribution Channel
10.1 Overview
10.2 Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
10.3 Endocrinologists
10.3.1 Overview
10.4 Immunologists
10.4.1 Overview
10.5 Rheumatologists
10.5.1 Overview
10.6 Oncologists
10.6.1 Overview
10.7 Dermatologists
10.7.1 Overview
10.8 Retina Compounding
10.8.1 Overview
10.9 Others
10.9.1 Overview
10.10 Hospital Pharmacies
10.10.1 Overview
10.10.2 Hospital Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.3 Endocrinologists
10.10.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.4 Immunologists
10.10.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.5 Rheumatologists
10.10.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.6 Oncologists
10.10.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.7 Dermatologists
10.10.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.8 Retina Specialists
10.10.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.10.9 Others
10.10.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11 Compounding Pharmacies
10.11.1 Overview
10.11.2 Compounding Pharmacies : Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.3 Endocrinologists
10.11.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.4 Immunologists
10.11.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.5 Rheumatologists
10.11.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.6 Oncologists
10.11.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.7 Dermatologists
10.11.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.8 Retina Specialists
10.11.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.11.9 Others
10.11.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12 Retail Pharmacies
10.12.1 Overview
10.12.2 Retail Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.3 Endocrinologists
10.12.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.4 Immunologists
10.12.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.5 Rheumatologists
10.12.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.6 Oncologists
10.12.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.7 Dermatologists
10.12.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.8 Retina Specialists
10.12.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.12.9 Others
10.12.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13 Online Pharmacies
10.13.1 Overview
10.13.2 Online Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.3 Endocrinologists
10.13.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.4 Immunologists
10.13.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.5 Rheumatologists
10.13.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.6 Oncologists
10.13.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.7 Dermatologists
10.13.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.8 Retina Specialists
10.13.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
10.13.9 Others
10.13.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
11. Europe Biosimilars Market – Revenue and Forecast to 2030 – Geographic Analysis
11.1 Europe Biosimilars Market, Revenue and Forecast to 2030
11.1.1 Overview
11.1.2 Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.1 Europe Biosimilars Market, by Disease Indication
11.1.2.2 Europe Biosimilars Market, by Autoimmune Diseases
11.1.2.3 Europe Biosimilars Market, by Route of Administration
11.1.2.4 Europe Biosimilars Market, by Drug Class
11.1.2.5 Europe Biosimilars Market, by Distribution Channel
11.1.2.6 Europe Biosimilars Market, by Hospital Pharmacies
11.1.2.7 Europe Biosimilars Market, by Compounding Pharmacies
11.1.2.8 Europe Biosimilars Market, by Retail Pharmacies
11.1.2.9 Europe Biosimilars Market, by Online Pharmacies
11.1.2.10 Europe Biosimilars Market by Country
11.1.2.10.1 Germany
11.1.2.10.1.1 Overview
11.1.2.10.1.2 Germany Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.1.2.1 Germany Biosimilars Market, by Disease Indication
11.1.2.10.1.2.2 Germany Biosimilars Market, by Autoimmune Diseases
11.1.2.10.1.2.3 Germany Biosimilars Market, by Route of Administration
11.1.2.10.1.2.4 Germany Biosimilars Market, by Drug Class
11.1.2.10.1.2.5 Germany Biosimilars Market, by Distribution Channel
11.1.2.10.1.2.6 Germany Biosimilars Market, by Hospital Pharmacies
11.1.2.10.1.2.7 Germany Biosimilars Market, by Compounding Pharmacies
11.1.2.10.1.2.8 Germany Biosimilars Market, by Retail Pharmacies
11.1.2.10.1.2.9 Germany Biosimilars Market, by Online Pharmacies
11.1.2.10.2 UK
11.1.2.10.3 Overview
11.1.2.10.3.1 UK Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.3.1.1 UK Biosimilars Market, by Disease Indication
11.1.2.10.3.1.2 UK Biosimilars Market, by Autoimmune Diseases
11.1.2.10.3.1.3 UK Biosimilars Market, by Route of Administration
11.1.2.10.3.1.4 UK Biosimilars Market, by Drug Class
11.1.2.10.3.1.5 UK Biosimilars Market, by Distribution Channel
11.1.2.10.3.1.6 UK Biosimilars Market, by Hospital Pharmacies
11.1.2.10.3.1.7 UK Biosimilars Market, by Compounding Pharmacies
11.1.2.10.3.1.8 UK Biosimilars Market, by Retail Pharmacies
11.1.2.10.3.1.9 UK Biosimilars Market, by Online Pharmacies
11.1.2.10.4 France
11.1.2.10.4.1 Overview
11.1.2.10.4.2 France Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.4.2.1 France Biosimilars Market, by Disease Indication
11.1.2.10.4.2.2 France Biosimilars Market, by Autoimmune Diseases
11.1.2.10.4.2.3 France Biosimilars Market, by Route of Administration
11.1.2.10.4.2.4 France Biosimilars Market, by Drug Class
11.1.2.10.4.2.5 France Biosimilars Market, by Distribution Channel
11.1.2.10.4.2.6 France Biosimilars Market, by Hospital Pharmacies
11.1.2.10.4.2.7 France Biosimilars Market, by Compounding Pharmacies
11.1.2.10.4.2.8 France Biosimilars Market, by Retail Pharmacies
11.1.2.10.4.2.9 France Biosimilars Market, by Online Pharmacies
11.1.2.10.5 Italy
11.1.2.10.5.1 Overview
11.1.2.10.5.2 Italy Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.5.2.1 Italy Biosimilars Market, by Disease Indication
11.1.2.10.5.2.2 Italy Biosimilars Market, by Autoimmune Diseases
11.1.2.10.5.2.3 Italy Biosimilars Market, by Route of Administration
11.1.2.10.5.2.4 Italy Biosimilars Market, by Drug Class
11.1.2.10.5.2.5 Italy Biosimilars Market, by Distribution Channel
11.1.2.10.5.2.6 Italy Biosimilars Market, by Hospital Pharmacies
11.1.2.10.5.2.7 Italy Biosimilars Market, by Compounding Pharmacies
11.1.2.10.5.2.8 Italy Biosimilars Market, by Retail Pharmacies
11.1.2.10.5.2.9 Italy Biosimilars Market, by Online Pharmacies
11.1.2.10.6 Spain
11.1.2.10.6.1 Overview
11.1.2.10.6.2 Spain Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.6.2.1 Spain Biosimilars Market, by Disease Indication
11.1.2.10.6.2.2 Spain Biosimilars Market, by Autoimmune Diseases
11.1.2.10.6.2.3 Spain Biosimilars Market, by Route of Administration
11.1.2.10.6.2.4 Spain Biosimilars Market, by Drug Class
11.1.2.10.6.2.5 Spain Biosimilars Market, by Distribution Channel
11.1.2.10.6.2.6 Spain Biosimilars Market, by Hospital Pharmacies
11.1.2.10.6.2.7 Spain Biosimilars Market, by Compounding Pharmacies
11.1.2.10.6.2.8 Spain Biosimilars Market, by Retail Pharmacies
11.1.2.10.6.2.9 Spain Biosimilars Market, by Online Pharmacies
11.1.2.10.7 Rest of Europe
11.1.2.10.7.1 Overview
11.1.2.10.7.2 Rest of Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.7.2.1 Rest of Europe Biosimilars Market, by Disease Indication
11.1.2.10.7.2.2 Rest of Europe Biosimilars Market, by Autoimmune Diseases
11.1.2.10.7.2.3 Rest of Europe Biosimilars Market, by Route of Administration
11.1.2.10.7.2.4 Rest of Europe Biosimilars Market, by Drug Class
11.1.2.10.7.2.5 Rest of Europe Biosimilars Market, by Distribution Channel
11.1.2.10.7.2.6 Rest of Europe Biosimilars Market, by Hospital Pharmacies
11.1.2.10.7.2.7 Rest of Europe Biosimilars Market, by Compounding Pharmacies
11.1.2.10.7.2.8 Rest of Europe Biosimilars Market, by Retail Pharmacies
11.1.2.10.7.2.9 Rest of Europe Biosimilars Market, by Online Pharmacies
12. Pre and Post COVID-19 Impact
12.1 Pre and Post COVID-19 Impact
13. Biosimilars Market – Industry Landscape
13.1 Overview
13.2 Growth Strategies in Biosimilars Market
13.3 Inorganic Growth Strategies
13.3.1 Overview
13.4 Organic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Amgen Inc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Celltrion Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Sanofi SA
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.4 Biocon Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Samsung Bioepis Co Ltd
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Eli Lilly and Co
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Sandoz AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Pfizer Inc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Dr. Reddy's Laboratories Ltd
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
List of Tables
Table 1. Comparison Between Different Drug Developments
Table 2. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 3. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 4. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 5. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 6. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 7. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 8. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 9. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 10. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 11. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 12. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 13. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 14. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 15. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 16. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 17. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 18. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 19. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 20. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 21. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 22. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 23. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 24. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 25. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 26. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 27. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 28. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 29. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 30. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 31. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 32. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 33. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 34. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 35. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 36. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 37. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 38. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 39. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 40. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 41. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 42. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 43. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 44. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 45. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 46. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 47. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 48. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 49. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 50. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 51. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 52. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 53. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 54. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 55. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 56. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Disease Indication
Table 57. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) – Autoimmune Diseases
Table 58. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Route of Administration
Table 59. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Drug Class
Table 60. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Distribution Channel
Table 61. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Hospital Pharmacies
Table 62. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Compounding Pharmacies
Table 63. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Retail Pharmacies
Table 64. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) – Online Pharmacies
Table 65. Recent Inorganic Growth Strategies in the Biosimilars Market
Table 66. Recent Organic Growth Strategies in Biosimilars Market
Table 67. Glossary of Terms
List of Figures
Figure 1. Biosimilars Market Segmentation
Figure 2. Biosimilars Market, by Region
Figure 3. Key Insights
Figure 4. Europe: PEST Analysis
Figure 5. Europe Biosimilars Market- Key Industry Dynamics
Figure 6. Europe Biosimilars Market: Impact Analysis of Drivers and Restraints
Figure 7. Europe Biosimilars Market – Revenue Forecast and Analysis – 2020–2030
Figure 8. Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
Figure 9. Cancer: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Autoimmune Diseases: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Psoriasis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Arthritis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
Figure 17. Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
Figure 21. Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Insulin: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 26. Hospital Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 33. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. Compounding Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 35. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 36. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 37. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 38. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 39. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 40. Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 41. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 42. Retail Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 43. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 44. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 45. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 46. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 47. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 48. Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 49. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 50. Online Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 51. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 52. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 53. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 54. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 55. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 56. Retina Compounding: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 57. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)
Figure 58. Europe Biosimilars Market, By Region, 2022 ($Mn)
Figure 59. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 60. Europe Biosimilars Market, By Key Countries, 2022 And 2030 (%)
Figure 61. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 62. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 63. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 64. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 65. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 66. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 67. Pre and Post COVID-19 Impact on Europe Biosimilars Market
Figure 68. Growth Strategies in Biosimilars Market
The List of Companies - Europe Biosimilars Market
- Amgen Inc
- Celltrion Inc
- Sanofi SA
- Biocon Ltd,
- Samsung Bioepis Co Ltd
- Elli Lilly and Co
- Sandoz AG
- Teva Pharmaceitical Industries Ltd
- Pfizer Inc
- Dr. Reddy's Laboratories Ltd
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Europe Biosimilars Market
Aug 2023
Laser-Assisted ENT Surgeries Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Laser Type (C02 Laser, Nd:YAG Laser, Diode Laser, Blue Laser, KTP Laser, Argon Laser, and Other Laser Types), Surgery Type [Laser Laryngeal Surgery, Laser Endoscopic Sinus Surgery (LESS), Laser-Assisted Uvulopalatoplasty (LAUP), Laser-Assisted Stapedotomy, Laser-Assisted Tonsillectomy and Adenoidectomy, Laser Turbinates Reduction, Transoral Laser Microsurgery (TLM), Nasal Surgery, and Other Surgery Types], End User (Hospitals and Specialty Clinics, Physician Offices, and Other End Users), and Geography (North America, Europe, Asia Pacific, South and Central America, and Middle East and Africa)
Aug 2023
Mobile Cleanroom Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Softwall and Hardwall), End User (Microelectronics Industry, Pharmaceuticals and Biotechnology Industry, Medical Device Manufacturers, and Others), and Geography
Aug 2023
Ovo-Sexing Technology Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technique (Non-Invasive Imaging, Genetic Editing, Volatile Analysis, Sex Reversal, and Liquid-Based Analysis), End User (Hatcheries and Poultry Farms), and Geography (US, Germany, France, Italy, Spain, Rest of Europe, Israel, and ROW)
Aug 2023
Dental Laser Treatment Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application (Hard Tissue, Soft Tissue, and Others), End User (Hospitals, Dental Clinics, Dental-Owned Practices, and Others), Clinical Indication [Conservative Dentistry, Root Canal (Endodontic Treatment), Oral Surgery, Implantology, Peri-Implantitis, Periodontics, and Others], and Geography
Aug 2023
Microbiology CRO Services Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application (Clinical, Medical Device, and Others), Service Type (Assay Development, Custom Viral Stock Production, Microbial Testing, and Others), Microorganisms (Bacteria, Fungi, Viruses, and Parasites), End User (Biotech and Pharmaceutical Companies, Medical Device Companies, and Others), and Geography
Aug 2023
Antimicrobial Surgical Suture Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Triclosan Antimicrobial Suture and Chlorhexidine Antimicrobial Suture), Raw Materials (Polyglactin 910 Antimicrobial Suture, Poliglecaprone 25, and Polyglycolic Acid), Application (Cardiovascular Surgery, General Surgery, Ophthalmic Surgery, Gynecological Surgery, Orthopedic Surgery, Plastic Surgery, Veterinary Surgery, Dental Surgery, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2023
Fall Management Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Sensor Pads, Floor Mat, Hip Protectors, Alert Systems, Communication Devices, and Other Products), Application (Fall Detection Systems, Fall Prevention Equipment, and Post-Fall Monitoring and Response Systems), Age Group [Elderly Population (65 and Above) and Adults (18–64 years)], End User (Hospitals and Clinics, Nursing Homes, Home Care Settings, and Other End Users), and Geography
Aug 2023
Organoids Services Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology Disease, Pathology of Infectious Disease, Regenerative Medicine, Drug Toxicity & Efficacy Testing, Drug Discovery & Personalized Medicine, and Others), Source (Pluripotent Stem Cells and Organ Specific Adult Stem Cell), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Get Free Sample For